Developer docs
API playgroundTry for free, no card

Search company profiles

SteriMax

Full company profile

uuid0009qq2

Namestring
SteriMax
Legal namestring
SteriMax Inc.
Websiteurl
sterimaxinc.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

SteriMax is a privately owned Canadian pharmaceutical company headquartered in Oakville, Ontario, that develops, manufactures, and distributes sterile injectable and specialty medicines. Founded in 1994 by pharmacist Mahen "Mike" Acharya and now led by his son Samir Acharya (President & CEO), the company operates a 45,000 sqft facility with in-house R&D and product development labs, Health Canada and FDA-approved quality control labs, and secondary packaging capabilities. Its portfolio of more than 50 products spans generic sterile injectables and branded specialty medicines across therapeutic areas including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology. The company supplies approximately 40 million doses annually from a single manufacturing site and serves Canadian hospitals, retail and specialty pharmacies, wholesalers and distributors, and national and regional hospital group purchasing organizations.

SteriMax's product strategy emphasizes ready-to-administer (RTU) convenience formats, room-temperature stability, and traceable 2D barcoded unit-of-use packaging, including the first Canadian room-temperature Fulvestrant pre-filled syringe (2025), Calcium Gluconate RTU bags with 24-month shelf life (2025), and Cisatracurium with a red safety warning ferrule aligned to ISMP and Health Canada best practices. Distribution combines direct enterprise sales, GPO contracts, wholesaler and specialty distributor partnerships, retail pharmacy banner relationships, and global export partners. Pricing follows transaction-based terms on NET 30 invoicing with a $500 minimum order threshold. The company also operates a Health Canada Tier 3 Exceptional Importation program to mitigate Canadian drug shortages, sourcing from both US-labelled and, more recently, Chinese-authorized supply.

Revenue is generated through one-time product sales across multiple customer verticals with no usage-based or subscription components; the business is internally financed by the Acharya family with no venture capital or private equity backing identified. The leadership team combines pharmaceutical operations (CSO Ritesh Acharya), commercial execution (CCO Edward Rajasingham, EVP Sales & Marketing Craig Potvin), and business development and licensing expertise (EVP Edward Morrison, EVP Innovation Hamed Ghanei), supporting ongoing portfolio expansion through organic launches and inbound licensing and acquisition activity.

Short descriptiontext

SteriMax is a privately owned Canadian pharmaceutical company that develops, manufactures, and distributes sterile injectable and specialty medicines, supplying hospitals, pharmacies, wholesalers, and GPOs across Canada from its Oakville, Ontario facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOakville, Canada
HQ citystring
Oakville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectables, generic pharmaceuticals, specialty medicines, ready-to-administer drugs, pharmaceutical manufacturing
Industry2 codes
PRIMARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAIABAL
Generic Hospital & Institutional Products
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Sterile Injectable Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Sterile Injectables
TypeOne Time License
Description

SteriMax generates revenue through the sale of generic sterile injectable products, including over 50 products across various therapeutic categories such as anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology.

sterimaxinc.com
2Branded Specialty Medicines
TypeOne Time License
Description

Revenue from branded medicines that address unmet medical needs through new and novel therapies, including both new chemical entities and reformulations of existing molecules.

sterimaxinc.com
3Exceptional Importation (Tier 3)
TypeOne Time License
Description

Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when supply is disrupted.

sterimaxinc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Standard Order Terms
ModelTransaction based/ take rateBilling cadenceAnnual
Notes

NET 30 payment terms from invoice date. Order minimum $500 with $50 handling fee for orders below. Rush orders subject to handling charge. Special delivery instructions may incur additional shipping charges.

sterimaxinc.com
2Special Product Ordering
ModelTransaction based/ take rateBilling cadenceAnnual
Notes

Narcotics & Controlled Drugs and Refrigerated/Cold Chain Items must be ordered separately from other product types, each meeting the $500 minimum value.

sterimaxinc.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SteriMax develops, manufactures, and distributes generic sterile injectable pharmaceuticals and branded specialty medicines for Canadian hospitals, pharmacies, and healthcare systems. The company offers over 50 products across therapeutic categories including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology, including proprietary ready-to-administer formats with 2D barcoding for medication safety.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40 million annual doses of medication supplied
+3 more records
Product overview1 text field

SteriMax is a privately owned Canadian pharmaceutical company and one of Canada's largest providers of sterile injectables and specialty medicines. The company operates a diversified portfolio of over 50 products organized into two main categories: Generic Medicines (sterile injectables designed for hospital, clinic, community and specialty care settings) and Branded Medicines (new medicines addressing unmet clinical needs through innovation and market access). The portfolio includes essential sterile injectables across therapeutic areas including anti-infectives, cardiovascular, critical care, oncology, electrolytes, hormones, anesthesia, and nutritional supplements. SteriMax delivers medicines directly to hospitals, pharmacies, wholesalers, and distributors through an end-to-end operational model encompassing regulatory affairs, product development, quality assurance, supply chain, and distribution. Notable products include Octreotide Injection, Magnesium Sulfate Injection USP, Cisatracurium Besylate Injection, Calcium Gluconate Injection Bags (ready-to-administer format), Doxycycline for Injection (first approved in Canada), and Fulvestrant Injection (first room-temperature stable format). The company supplies approximately 40 million annual doses and employs 200 people at its Oakville, Ontario facility.

Product and service4 records
1Generic Sterile Injectables Portfolio
CategoryGeneric Medicines
Description

SteriMax's core portfolio of over 50 generic sterile injectable medicines across therapeutic categories including anti-infectives, cardiovascular, critical care, electrolytes, hormones, oncology, and anesthesia, designed for hospital, clinic, community, and specialty care settings in Canada.

2Branded Specialty Medicines
CategoryBranded Medicines
Description

Branded medicines addressing unmet clinical needs through new and novel therapies, including new chemical entities and reformulations of existing molecules brought to the Canadian market through partnerships with global pharmaceutical companies.

3Tier 3 Exceptional Importation Service
CategoryExceptional Importation
Description

Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when domestic supply is disrupted.

4Calcium Gluconate in Sodium Chloride Injection Bags (Ready-to-Administer)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthers
Description

GFL Environmental Services Inc. handles expired product returns processing for SteriMax. Customers return expired products within 12 months after expiration to GFL at 76 Wentworth Court, Brampton, ON, L6T 5M7.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SteriMax partners with global and regional pharmaceutical companies to bring generic and branded medicines to market, improving patient access and addressing unmet medical needs. Includes both new chemical entities and reformulations of existing molecules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strong and longstanding relationships with National and Regional Hospital Group purchasing organizations, key provincial healthcare leadership, distributors, specialty pharmacies, and retail pharmacy banners across Canada.

4Global Export Partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnerships with regional healthcare companies to deliver essential medicines beyond Canada, reinforcing healthcare systems in markets that depend on consistent supply.

sterimaxinc.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In 2004, SteriMax acquired five injectable products from Novartis, solidifying its market position as a provider of niche, small-volume sterile injectable products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Sandoz
TypeBroad incumbent
Description

Sandoz is the global leader in generic sterile injectable pharmaceuticals with a broad hospital injectable portfolio across therapeutic areas. It directly competes with SteriMax in generic sterile injectables, but at much larger global scale, serving the same hospital and pharmacy channels.

TypeBroad incumbent
Description

Fresenius Kabi is a major global manufacturer of sterile injectable generics, infusion solutions, and clinical nutrition products. It overlaps with SteriMax's hospital injectable portfolio and was a previous employer of SteriMax's EVP Sales & Marketing, reflecting direct industry overlap.

TypeDirect peer
Description

Hikma is a specialty generic injectable manufacturer with a strong North American hospital franchise. It directly competes with SteriMax in generic sterile injectables across similar therapeutic categories, including anti-infectives, cardiovascular, and oncology.

4Hospira (Pfizer Injectables)
TypeBroad incumbent
Description

Pfizer's hospital injectable business (formerly Hospira) is a global leader in sterile injectable pharmaceuticals. It directly competes with SteriMax in many of the same generic injectable molecules and supplies Canadian hospitals through similar distribution channels.

TypeDirect peer
Description

Amphastar is a US-based specialty pharmaceutical company focused on injectable and inhalation products, including niche sterile injectables. It is comparable to SteriMax in product mix (niche injectables), hospital customer focus, and specialty product positioning.

TypeBroad incumbent
Description

Teva is one of the largest generic pharmaceutical manufacturers globally with a substantial sterile injectable portfolio. It overlaps with SteriMax across generic injectables and serves similar hospital, pharmacy, and distribution channels in North America.

TypeDirect peer
Description

Apotex is Canada's largest generic pharmaceutical manufacturer with a portfolio that includes sterile injectables and serves Canadian hospitals and pharmacies. It is a direct domestic peer to SteriMax, competing for hospital and GPO contracts in Canada.

TypeBroad incumbent
Description

Aurobindo is a global generic pharmaceutical manufacturer with a growing sterile injectable portfolio serving North American markets. It overlaps with SteriMax in generic injectable therapeutic categories and competes in similar hospital channels.

TypeBroad incumbent
Description

Dr. Reddy's is a global pharmaceutical company with a substantial sterile injectable franchise in North America, including oncology and hospital injectables. It competes with SteriMax in many of the same molecules and customer segments.

TypeRegional player
Description

Medicure is a Canadian specialty pharmaceutical company with branded hospital products including cardiovascular injectables. It shares SteriMax's Canadian market focus, hospital customer base, and branded/specialty product strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SteriMax

Generic Sterile Injectable Pharmaceuticalssterimaxinc.com

SteriMax is a privately owned Canadian pharmaceutical company that develops, manufactures, and distributes sterile injectable and specialty medicines, supplying hospitals, pharmacies, wholesalers, and GPOs across Canada from its Oakville, Ontario facility.

What SteriMax does

SteriMax is a privately owned Canadian pharmaceutical company headquartered in Oakville, Ontario, that develops, manufactures, and distributes sterile injectable and specialty medicines. Founded in 1994 by pharmacist Mahen "Mike" Acharya and now led by his son Samir Acharya (President & CEO), the company operates a 45,000 sqft facility with in-house R&D and product development labs, Health Canada and FDA-approved quality control labs, and secondary packaging capabilities. Its portfolio of more than 50 products spans generic sterile injectables and branded specialty medicines across therapeutic areas including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology. The company supplies approximately 40 million doses annually from a single manufacturing site and serves Canadian hospitals, retail and specialty pharmacies, wholesalers and distributors, and national and regional hospital group purchasing organizations.

SteriMax's product strategy emphasizes ready-to-administer (RTU) convenience formats, room-temperature stability, and traceable 2D barcoded unit-of-use packaging, including the first Canadian room-temperature Fulvestrant pre-filled syringe (2025), Calcium Gluconate RTU bags with 24-month shelf life (2025), and Cisatracurium with a red safety warning ferrule aligned to ISMP and Health Canada best practices. Distribution combines direct enterprise sales, GPO contracts, wholesaler and specialty distributor partnerships, retail pharmacy banner relationships, and global export partners. Pricing follows transaction-based terms on NET 30 invoicing with a $500 minimum order threshold. The company also operates a Health Canada Tier 3 Exceptional Importation program to mitigate Canadian drug shortages, sourcing from both US-labelled and, more recently, Chinese-authorized supply.

Revenue is generated through one-time product sales across multiple customer verticals with no usage-based or subscription components; the business is internally financed by the Acharya family with no venture capital or private equity backing identified. The leadership team combines pharmaceutical operations (CSO Ritesh Acharya), commercial execution (CCO Edward Rajasingham, EVP Sales & Marketing Craig Potvin), and business development and licensing expertise (EVP Edward Morrison, EVP Innovation Hamed Ghanei), supporting ongoing portfolio expansion through organic launches and inbound licensing and acquisition activity.

SteriMax firmographics

Firmographics
Name
SteriMax
Legal name
SteriMax Inc.
Website
https://sterimaxinc.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
101–250 employees
Short description
SteriMax is a privately owned Canadian pharmaceutical company that develops, manufactures, and distributes sterile injectable and specialty medicines, supplying hospitals, pharmacies, wholesalers, and GPOs across Canada from its Oakville, Ontario facility.
Ownership category
akta.pro rank

SteriMax industry classification

Industry
Product category
Generic Sterile Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAC
Sterile Injectable Generics
SECONDARYHLAIABAL
Generic Hospital & Institutional Products

Keywords

  • Sterile injectables
  • Generic pharmaceuticals
  • Specialty medicines
  • Ready-to-administer drugs
  • Pharmaceutical manufacturing

Where SteriMax is headquartered

Location

Headquarters

HQ city
Oakville
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

SteriMax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Generic Sterile Injectables: SteriMax generates revenue through the sale of generic sterile injectable products, including over 50 products across various therapeutic categories such as anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology.
  2. Branded Specialty Medicines: Revenue from branded medicines that address unmet medical needs through new and novel therapies, including both new chemical entities and reformulations of existing molecules.
  3. Exceptional Importation (Tier 3): Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when supply is disrupted.

Pricing tiers

ModelBillingPrice
Transaction based/ take rateAnnualStandard Order Terms
Transaction based/ take rateAnnualSpecial Product Ordering

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

SteriMax product offering

Product offering

Core offering

SteriMax develops, manufactures, and distributes generic sterile injectable pharmaceuticals and branded specialty medicines for Canadian hospitals, pharmacies, and healthcare systems. The company offers over 50 products across therapeutic categories including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology, including proprietary ready-to-administer formats with 2D barcoding for medication safety.

Product overview

SteriMax is a privately owned Canadian pharmaceutical company and one of Canada's largest providers of sterile injectables and specialty medicines. The company operates a diversified portfolio of over 50 products organized into two main categories: Generic Medicines (sterile injectables designed for hospital, clinic, community and specialty care settings) and Branded Medicines (new medicines addressing unmet clinical needs through innovation and market access). The portfolio includes essential sterile injectables across therapeutic areas including anti-infectives, cardiovascular, critical care, oncology, electrolytes, hormones, anesthesia, and nutritional supplements. SteriMax delivers medicines directly to hospitals, pharmacies, wholesalers, and distributors through an end-to-end operational model encompassing regulatory affairs, product development, quality assurance, supply chain, and distribution. Notable products include Octreotide Injection, Magnesium Sulfate Injection USP, Cisatracurium Besylate Injection, Calcium Gluconate Injection Bags (ready-to-administer format), Doxycycline for Injection (first approved in Canada), and Fulvestrant Injection (first room-temperature stable format). The company supplies approximately 40 million annual doses and employs 200 people at its Oakville, Ontario facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Sterile Injectables Portfolio SteriMax's core portfolio of over 50 generic sterile injectable medicines across therapeutic categories including anti-infectives, cardiovascular, critical care, electrolytes, hormones, oncology, and anesthesia, designed for hospital, clinic, community, and specialty care settings in Canada.
  • Branded Specialty Medicines Branded medicines addressing unmet clinical needs through new and novel therapies, including new chemical entities and reformulations of existing molecules brought to the Canadian market through partnerships with global pharmaceutical companies.
  • Tier 3 Exceptional Importation Service Importation of foreign-authorized medications to address critical Tier 3 drug shortages in Canada, providing essential medicines when domestic supply is disrupted.
  • Calcium Gluconate in Sodium Chloride Injection Bags (Ready-to-Administer)

Quantifiable outcome

  • 40 million annual doses of medication supplied
  • +3 more outcomes

Companies that use SteriMax

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

SteriMax technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

SteriMax partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • GFL Environmental Services Inc.minorOthersGFL Environmental Services Inc. handles expired product returns processing for SteriMax. Customers return expired products within 12 months after expiration to GFL at 76 Wentworth Court, Brampton, ON, L6T 5M7.
  • Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerSteriMax partners with global and regional pharmaceutical companies to bring generic and branded medicines to market, improving patient access and addressing unmet medical needs. Includes both new chemical entities and reformulations of existing molecules.
  • Healthcare Systems and Hospital GroupscoreStrategic or Co-development PartnerStrong and longstanding relationships with National and Regional Hospital Group purchasing organizations, key provincial healthcare leadership, distributors, specialty pharmacies, and retail pharmacy banners across Canada.
  • Global Export PartnersminorChannel Partner/ Reseller/ DistributorPartnerships with regional healthcare companies to deliver essential medicines beyond Canada, reinforcing healthcare systems in markets that depend on consistent supply.
  • NovartiscoreStrategic or Co-development PartnerIn 2004, SteriMax acquired five injectable products from Novartis, solidifying its market position as a provider of niche, small-volume sterile injectable products.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

SteriMax competitors and assessment

Company assessment

Broad incumbents

  • Sandoz: Sandoz is the global leader in generic sterile injectable pharmaceuticals with a broad hospital injectable portfolio across therapeutic areas. It directly competes with SteriMax in generic sterile injectables, but at much larger global scale, serving the same hospital and pharmacy channels.
  • Fresenius Kabi: Fresenius Kabi is a major global manufacturer of sterile injectable generics, infusion solutions, and clinical nutrition products. It overlaps with SteriMax's hospital injectable portfolio and was a previous employer of SteriMax's EVP Sales & Marketing, reflecting direct industry overlap.
  • Hospira (Pfizer Injectables): Pfizer's hospital injectable business (formerly Hospira) is a global leader in sterile injectable pharmaceuticals. It directly competes with SteriMax in many of the same generic injectable molecules and supplies Canadian hospitals through similar distribution channels.
  • Teva Pharmaceutical Industries: Teva is one of the largest generic pharmaceutical manufacturers globally with a substantial sterile injectable portfolio. It overlaps with SteriMax across generic injectables and serves similar hospital, pharmacy, and distribution channels in North America.
  • Aurobindo Pharma: Aurobindo is a global generic pharmaceutical manufacturer with a growing sterile injectable portfolio serving North American markets. It overlaps with SteriMax in generic injectable therapeutic categories and competes in similar hospital channels.
  • Dr. Reddy's Laboratories: Dr. Reddy's is a global pharmaceutical company with a substantial sterile injectable franchise in North America, including oncology and hospital injectables. It competes with SteriMax in many of the same molecules and customer segments.

Direct peers

  • Hikma Pharmaceuticals: Hikma is a specialty generic injectable manufacturer with a strong North American hospital franchise. It directly competes with SteriMax in generic sterile injectables across similar therapeutic categories, including anti-infectives, cardiovascular, and oncology.
  • Amphastar Pharmaceuticals: Amphastar is a US-based specialty pharmaceutical company focused on injectable and inhalation products, including niche sterile injectables. It is comparable to SteriMax in product mix (niche injectables), hospital customer focus, and specialty product positioning.
  • Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer with a portfolio that includes sterile injectables and serves Canadian hospitals and pharmacies. It is a direct domestic peer to SteriMax, competing for hospital and GPO contracts in Canada.

Regional players

  • Medicure Inc. Medicure is a Canadian specialty pharmaceutical company with branded hospital products including cardiovascular injectables. It shares SteriMax's Canadian market focus, hospital customer base, and branded/specialty product strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights1 record

Customer concentration

SteriMax social profiles

Digital presence

SteriMax compliance and trust

Trust signal

Compliance1 record

SteriMax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SteriMax leadership team

Management profile

Number of profiles

Profiles8 records

SteriMax funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SteriMax M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SteriMax

What does SteriMax do?

SteriMax develops, manufactures, and distributes generic sterile injectable pharmaceuticals and branded specialty medicines for Canadian hospitals, pharmacies, and healthcare systems. The company offers over 50 products across therapeutic categories including anesthetics, anti-infectives, cardiovascular, critical care, electrolytes, hormones, and oncology, including proprietary ready-to-administer formats with 2D barcoding for medication safety.

Is SteriMax a public or private company?

SteriMax is a private company. It is classified as family owned and is currently operating.

When was SteriMax founded?

SteriMax was founded in 1994. It employs 101 to 250 people.

Where is SteriMax based?

SteriMax is headquartered in Oakville, Canada, in the North America region.

How does SteriMax make money?

Three revenue lines are on record. Generic Sterile Injectables are the primary driver. The others are branded Specialty Medicines and exceptional Importation (Tier 3).

Who are SteriMax's main competitors?

Broad incumbents on record are Sandoz, Fresenius Kabi, Hospira (Pfizer Injectables), Teva Pharmaceutical Industries, Aurobindo Pharma and Dr. Reddy's Laboratories. Direct peers are Hikma Pharmaceuticals, Amphastar Pharmaceuticals and Apotex Inc.. Medicure Inc. is listed as a regional player.

Does SteriMax have an API?

No public API is recorded for SteriMax.

What industry is SteriMax in?

SteriMax's product category is Generic Sterile Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAC, Sterile Injectable Generics, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BeckershospitalreviewIfosfamide shortage turns ‘critical,’ FDA to allow overseas importsThe American Society of Clinical Oncology said on Aug. 25 that the U.S. shortage of chemotherapy drug ifosfamide has reached a "critical" stage. The FDA is allowing overseas manufacturers to temporarily import the drug, and SteriMax USA and distributor GlobalRX said on Aug. 21 they would begin importing and distributing vials of Ifosfamide for Injection, which is not currently FDA-approved.Pulse 2.0Why SteriMax Acquired Andone PharmaceuticalsSteriMax has acquired Andone Pharmaceuticals, a Canadian pharmaceutical and medical device company based in Oakville, Ontario, with financial terms undisclosed. The acquisition strengthens SteriMax's position as one of Canada's largest privately owned pharmaceutical companies and expands its platform into the medical device and veterinary markets. Andone founder Jay Barat will join SteriMax to lead these newly acquired business verticals.PR NewswireSteriMax Acquires Andone Pharmaceuticals, Expanding into Medical Device and Veterinary MarketsSteriMax Inc., a Canadian pharmaceutical company specializing in sterile injectables, has acquired Andone Pharmaceuticals Inc., also based in Oakville, Ontario. The acquisition broadens SteriMax's portfolio into medical device and veterinary markets while adding Andone's three commercial verticals. Andone founder Jay Barat will join SteriMax to lead these newly acquired business lines.SterimaxincSteriMax Announces Acquisition of Andone Pharmaceuticals, Expanding Presence in Medical Device and Veterinary MarketsSteriMax Inc. acquired Andone Pharmaceuticals, a Canadian pharmaceutical and medical device company, to expand into veterinary and medical device markets. Andone's three commercial verticals complement SteriMax's injectable portfolio, and founder Jay Barat will lead the veterinary and medical device businesses. The combined portfolios aim to better serve healthcare providers across a broader spectrum of care.NewswireSteriMax Acquires Andone Pharmaceuticals, Expanding into Medical Device and Veterinary MarketsSteriMax Inc. acquired Andone Pharmaceuticals, a Canadian pharmaceutical and medical device company, to expand into veterinary and medical device markets. Andone's three commercial verticals complement SteriMax's injectable portfolio, and founder Jay Barat will lead the veterinary and medical device businesses. The combined portfolios aim to better serve healthcare providers across a broader spectrum of care.PR NewswireGlobal Tardive Dyskinesia Therapeutics Market Analysis & Forecast 2024-2034 - Hospital Pharmacies Lead Distribution ChannelsResearchAndMarkets.com has released a market analysis report on the global tardive dyskinesia therapeutics market, projecting growth from USD 3.59 billion in 2023 to USD 9.56 billion by 2034, representing a compound annual growth rate of 9.31%. Valbenazine led revenue in 2023, while hospital pharmacies held the largest distribution channel share, with North America currently dominating the market and Asia Pacific expected to see exponential growth. The report profiles key companies in the competitive landscape including Neurocrine Biosciences, Teva Pharmaceutical, AbbVie, and Sun Pharmaceutical Industries.